Biopharmaceutical Manufacturing: The Challenge of Global Regulatory Compliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biopharmaceutical Manufacturing: The Challenge of Global Regulatory Compliance
This article provides an overview of regulatory issues facing companies that seek to market their biopharmaceutical agents globally, including a trend toward harmonization of requirements as well as the differences in rules concerning applications, GMP standards, and communication with reviewers.


Pharmaceutical Technology


References

1. History and Future of ICH, http://www.ich.org/cache/html/355-272-1.html, accessed November 1, 2007.

2. Synopsis of ICH Guidelines and Topics, May 18, 2004, http://www.ich.org/cache/compo/276-254-1.html.

3. FDA, Guideline for Drug Master Files (Bethesda, MD, Sept. 1989).

4. S.M. Wheelwright and H. Kosaku, Changes to the Japanese Pharmaceutical Affairs Law, http://pharmalicensing.com/articles/disp/1114519858_426e3932b5e95, accessed Nov. 5, 2007.

5. Committee for Proprietary Medicinal Products, Note for Guidance on Summary of Requirements for Active Substances in Part II of the Dossier (The European Agency for the Evaluation of Medicinal Products, London, UK, Jan. 1998).

6. P. D'Eramo, "Japan's Pharmaceutical Affairs Law (PAL): Opportunities and Challenges," http://www.ispe.org/cs/root/regulatory_resources/regulatory_review_article_archives/february_2007_japans_pharmaceutical_affairs_law_pal_opportunities_and_challenges/, accessed November 5, 2007.

7. Good Clinical Practice — Human Medicinal Products, http://www.emea.europa.eu/Inspections/GCPgeneral.html, accessed Nov. 7, 2007.

8. M.W. Matthews and R. Winslow, "New FDA Rules will Expedite Testing of Drugs," Wall Street Journal: Eastern Edition, Jan. 12, 2006, pp. –B6.

9. FDA, Compliance Program Guidance Manual: Active Pharmaceutical Ingredient Process Inspection (Bethesda, MD, Feb. 13, 2006).

10. R. Horan, "FDA CGMP Inspections," 2005 FDA CGMP China Training Program (Dec. 14, 2005), http://www.fda.gov/cder/meeting/CTP2005.htm, accessed Nov. 4, 2007.

11. A.M. Thayer, "Europe Adopts GMP Regulations," Chem. Eng. News 84 (7), 29–33 (2006).

12. FDA, "Innovation and Continuous Improvement in Pharmaceutical Manufacturing," Pharmaceutical CGMPs for the 21st Century, http://www.fda.gov/cder/gmp/gmp2004/manufSciWP.pdf, accessed Nov. 5, 2007.

13. A. Katsnelson, "FDA and EMEA Pool Scientific Advice," Nat Biotechnol. 22(12), 1490–1491(2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here